2006 Fiscal Year Final Research Report Summary
The search of the gene polymorphism associated with glycolipid metabolism dysfunction in schizophrenic patients with novel antipsychotics
| Project/Area Number |
17591199
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Single-year Grants |
|---|
| Section | 一般 |
|---|
| Research Field |
Psychiatric science
|
|---|
| Research Institution | Niigata University |
|---|
Principal Investigator |
SOMEYA Toshiyuki Niigata University, Institute of Medicine and Dentistry, Professor, 医歯学系, 教授 (50187902)
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
SUZUKI Yutaro Niigata University, Medical and Dental Hospital, Lecturer, 医歯学総合病院, 講師 (60377158)
MURATAKE Tatsuyuki Niigata University, Medical and Dental Hospital, Lecturer, 医歯学総合病院, 講師 (60311669)
|
|---|
| Project Period (FY) |
2005 – 2006
|
| Keywords | novel antipsychotics / schizophrenia / glucose intolerance / clinical response / dopamine D2 receptor / Taq1A gene / prolactin |
|---|
| Research Abstract |
Novel antipsychotics, such as risperidone, olanzapine, quetiapine, perospirone and aripiprazole, have played an important role in the treatment of schizophrenia. These drugs have significant clinical advantages compared to conventional antipsychotics, i.e. lesser side effects such as extrapyramidal symptoms, oversedation and cognitive impairment. On the contrary they have higher risk of different cluster of side effects such as glycolipid metabolism dysfunction and obesity. There are also wide interindividual variations among patients in glycolipid metabolism dysfunction, in the same way as clinical response and susceptibility to other adverse effects. Therefore it is strongly required that the mechanism of these interindividual diversities are cleared up and individualized pharmacotherapy based on the mechanism is developed.
In this study, we have obtained 200 schizophrenic cases treated with antipsychotics and are still increasing the number of samples, in order to explore the relationship of interindividual diversity including genetic polymorphisms with response and/or adverse effects against the antipsychotics.
So far, we obtained the results such as ;
1.A1carrier of dopamine D2 receptor Taq1A gene showed significant higher improvement in % reduction of BPRS score compared to Al non-carriers.
2.There was an apparent gender difference in drug-induced prolactin elevation and longitudinal changes.
3.A perospirone metabolite concentration in plasma, ID150326, showed a greater impact on prolactin levels than parent compound perospirone did.
|
